Vision. Connection. Innovation.

video of the thread

about us.

Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology.

Pipeline

  1. GB001

    DP2 antagonist – moderate to severe eosinophilic asthma. Phase 2b ongoing.

  2. GB001

    DP2 antagonist – chronic rhinosinusitis with nasal polyps. Phase 2 planned.

  3. GB001

    DP2 antagonist – chronic spontaneous urticaria. Phase 2 planned.

  4. GB002

    PDGF receptor kinase inhibitor – pulmonary arterial hypertension. Phase 1 ongoing.

  5. GB004

    HIF-1a stabilizer – Inflammatory Bowel Disease. Phase 1 ongoing.

  6. GB1275

    CD11b agonist. Preclinical program.

  7. Autoimmune Program

    Preclinical program*

  8. Oncology
    Program

    Research program*

  1. GB001

    DP2 antagonist – moderate to severe eosinophilic asthma. Phase 2b ongoing.

  2. GB001

    DP2 antagonist – chronic rhinosinusitis with nasal polyps. Phase 2 planned.

  3. GB001

    DP2 antagonist – chronic spontaneous urticaria. Phase 2 planned.

*Targets to be disclosed

scroll